1. Scrip

'I Was Disappointed,' Pfizer CEO Bourla Says Of US Presidential Debate

 
• By Jessica Merrill

Pfizer CEO Albert Bourla said he is disappointed in the US politicization of a COVID-19 vaccine in a letter to employees. "We are moving at the speed of science," he said.

Albert Bourla
Pfizer CEO Albert Bourla • Source: Shutterstock

Pfizer Inc. CEO Albert Bourla was compelled to release an unusual letter to employees addressing the politicization of a COVID-19 vaccine following the US presidential debate on 29 September, when both presidential candidates raised doubts about the timeline for developing a vaccine.

"Tuesday night I joined millions of Americans who tuned in to the Presidential debate," he said in the 1 October memo

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

More from Scrip

Finance Watch: Unity Lays Off All Employees As It Evaluates Alternatives

 
• By Mandy Jackson

Restructuring Edition: Unity unveiled more Phase IIb data for lead asset UBX1325 along with plans to shed its workforce while seeking a partner for it and other drugs. Also, Ono is consolidating US employees at one site, Entrada is cutting its workforce by 20% and other recent strategic shifts.

In Brief: Genmab To Seek FDA Nod For Epkinly In Lymphoma

 
• By Sushmita Panda

Genmab will submit an sBLA for Epkinly in R/R follicular lymphoma in H1 2025, backed by positive Phase III data.

Pharma Predicts Modest Impact From Tariffs, But It Depends On What Comes Next

 
• By Jessica Merrill

Drugmakers aren’t expecting a big financial hit from tariffs for now, but a report commissioned by PhRMA suggests the cost of pharma-sector tariffs could be steep.